Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 36 clinical trials
Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble)

leiomyosarcomas or other metastatic uterine tumours.

  • 2 views
  • 12 Feb, 2022
  • 4 locations
Phase II Study of Regorafenib as Maintenance Therapy

Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as 1st line chemotherapy.

  • 2 views
  • 08 Feb, 2022
  • 18 locations
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (APROMISS)

THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA.

ejection fraction
measurable disease
angiogenesis
anthracyclines
alveolar soft part sarcoma
  • 334 views
  • 27 Jan, 2022
  • 22 locations
Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

(dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or

dedifferentiated liposarcoma
measurable disease
leiomyosarcoma
neutrophil count
systemic therapy
  • 0 views
  • 30 Jul, 2021
  • 23 locations
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases

The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

measurable disease
rituximab
fever
systemic disease
colony stimulating factor
  • 1 views
  • 11 Oct, 2022
  • 37 locations
An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

This study will evaluate the safety efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma

metastatic nasopharyngeal carcinoma
nasopharyngeal carcinoma
measurable disease
carcinoma
chemotherapy regimen
  • 0 views
  • 14 Oct, 2022
  • 17 locations
ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101)

The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma (LPS) and leiomyosarcoma (LMS). ATX-101 is an

advanced sarcoma
measurable disease
leiomyosarcoma
immunomodulators
neutrophil count
  • 0 views
  • 04 Oct, 2022
Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma

advanced or metastatic leiomyosarcoma who are inoperable are enrolled, aiming at the effectiveness and safety of temozolomide for injection combined with epirubicin as the first-line treatment for advanced

cancer
measurable disease
metastasis
leiomyosarcoma
cancer chemotherapy
  • 0 views
  • 24 Mar, 2022
  • 1 location
A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma

Multi-center, open-label, Phase I/II dose escalation and expansion trial of TTI-621 in patients with unresectable or metastatic high-grade leiomyosarcoma.

measurable disease
angiosarcoma
doxorubicin
epithelioid sarcoma
undifferentiated pleomorphic sarcoma
  • 14 views
  • 04 Oct, 2022
  • 22 locations
Lurbinectedin + Doxorubicin In Leiomyosarcoma

lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine which is more effective at treating leiomyosarcoma, lurbinectedin with doxorubicin or

  • 0 views
  • 23 Mar, 2022
  • 2 locations